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Abstract: Background & Aims: In approximately 70% of patients
with hepatocellular carcinoma (HCC) treated by resection or ablation,
disease recurs within 5 years. Although gene expression signatures
have been associated with outcome, there is no method to predict
recurrence based on combined clinical, pathology, and genomic data
(from tumor and cirrhotic tissue). We evaluated gene expression sig-
natures associated with outcome in a large cohort of patients with
early stage (Barcelona-Clinic Liver Cancer 0/A), single-nodule HCC
and heterogeneity of signatures within tumor tissues.
Methods:We assessed 287 HCC patients undergoing resection and
tested genome-wide expression platforms using tumor (n = 287)
and adjacent non-tumor, cirrhotic tissue (n = 226). We evaluated
gene expression signatures with reported prognostic ability gener-
ated from tumor or cirrhotic tissue in 18 and four reports, respec-
tively. In 15 additional patients, we proﬁled samples from the
center and periphery of the tumor, to determine stability of signa-
tures. Data analysis included Cox modeling and random survival for-
ests to identify independent predictors of tumor recurrence.
Results: Gene expression signatures that were associated with
aggressive HCC were clustered, as well as those associated with
tumors of progenitor cell origin and those from non-tumor, adjacent,
cirrhotic tissues. On multivariate analysis, the tumor-associated sig-
nature G3-proliferation (hazard ratio [HR], 1.75; P = .003) and an
adjacent poor-survival signature (HR, 1.74; P = .004) were indepen-
dent predictors of HCC recurrence, along with satellites (HR, 1.66;
P = .04). Samples from different sites in the same tumor nodule were
reproducibly classiﬁed.Journal of Hepatology 20
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Large scale biological data capturing and analysis has revolution-
ized biomedical research over the past decade [1]. Among the
diverse omics technologies transcriptome proﬁling by means of
microarray analysis is one of the most advanced technologies,
where expression levels of thousands of genes are measured at
once [2]. High expectations exist that the analysis of large scale
gene expression pattern will result in a better understanding of
the molecular basis of multifactorial disorders, such as hepatocel-
lular carcinoma (HCC).
A common goal of large scale transcriptome proﬁling is the
stratiﬁcation of patients eventually leading to personalized prog-
nostic predictions and therapeutic strategies. In particular, the
approach to biomarker discovery and development in clinical
research made considerable use of microarray technologies. In
breast cancer this vision was forcefully pursued. The 70-gene
MammaPrint proﬁle [3] and the 21-gene Oncotype DX [4] signa-
ture represent pioneering signatures aimed to determine an indi-
vidualized beneﬁt of chemotherapy and an individualized risk for
metastasis. Although commercially available these genetic test-
ing platforms have not entered clinical routine applications in
cancer treatment. Currently most promising is a 76-gene out-
come clinical proﬁle (Rotterdam signature [5]), demonstrated to
be of prognostic value in patients with node-negative (N0) breast
cancer. This signature was conﬁrmed in a larger cohort and is
now further investigated in an ongoing European clinical trial
(MINDACT, Microarray In Node negative Disease may Avoid
ChemoTherapy, EORTC Trial 10041).
However, despite all technological advances and progress in
technology and bioinformatics algorithms for a sophisticated
analysis, still major challenges in microarray analysis exist in
all the biological, technological, statistical, and informatic aspects
of this technology. Among the most discussed difﬁculties are:
sample collection, sampling issues, technical variation, validation
of results, and bioinformatics approaches to analysis [2]. These12 vol. 56 j 279–281
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challenges still prevent a rapid introduction of gene expression
proﬁle in clinical decision processes.
Over the past several years multiple signatures of a few genes
supposed to be driver genes in particular biological phenomena
have been published addressing HCC development, HCC recur-
rence, metastasis of HCC, vascular invasion of HCC, and others.
Although all of these signatures had signiﬁcant predictive ability,
the successful translation and rigorous evaluation for a clinical
application is yet to be generated [6].
In the May issue of Gastroenterology Villaneuva et al.
published a comprehensive analysis of transcriptomic changes
predicting the recurrence of HCC after surgical resection [7].
This work evaluated gene expression signatures associated with
outcome in a large cohort of patients with early stage
(Barcelona-Clinic Liver Cancer 0/A), single-nodule HCC and
heterogeneity of signatures within tumor tissues. In conclusion
the authors developed a composite prognostic model for HCC
recurrence, based on gene expression patterns in tumor and
adjacent tissues. These signatures predict early and overall
recurrence in patients with HCC, and complement ﬁndings from
clinical and pathology analyses.
As a major contribution to the progress of discovery and
evaluation of genetic signatures, Villaneuva et al. provide a
comprehensive evaluation of 22 previously published genetic
signatures. These data will certainly be valuable on the way to
establishing robust andmeaningful signatures with a clear impact
on clinical decision making.
Interestingly most signatures previously reported could be
conﬁrmed in this independent data set. Seventeen out of these
signatures were able to adequately allocate patients in a poor
or good prognosis group. Of note, two of these signatures were
obtained from adjacent non-tumoral tissue, emphasizing the crit-
ical role for the adjacent non-tumoral tissue in HCC development.
Also, these signatures obtained from non-tumor adjacent tissue
were not signiﬁcantly associated with the signatures from the
tumor. Thus, integrating this complimentary information into a
comprehensive predictive signature may hold even more
accuracy for the future.
The signatures to be veriﬁed have initially not necessarily been
described in comparable early stages of HCC. This may explain the
fact that some signatures could not be conﬁrmed. However, it is
noteworthy that none of the investigated signatures identifying
a progenitor cell origin, EpCAM, hepatoblastoma-C2, CK19-rat,
and CK19-human signature could be conﬁrmed to be of prognos-
tic value in the presented analysis of early tumor stages. Although
a potential contribution of stem/progenitor cells to the develop-
ment of HCC is still a matter of debate, evidence for the concept
of cancer stem/progenitor cells has been accumulated over the
past several years. With respect to epithelial cell adhesion
molecule (EpCAM), EpCAM-positive cells were demonstrated to
possess stem cell characteristics as transplantation of human
derived EpCAM+ cells into NOD/SCID mice after propagation in
tissue culture results in mature liver tissue expressing human-
speciﬁc proteins. Recently, several xenograft transplantation
experiments using stem cell/progenitor cell exhibiting markers
suggested a contribution of these progenitor cells to HCC develop-
ment. Among them EpCAM+ HCC cells from alpha-fetoprotein
AFP+ tumors with cancer stem/progenitor cell features exhibited
the abilities to self-renew, differentiate, and initiate aggressive
tumors in vivo. Since these tumor initiating capabilities of
EpCAM+ cells should be of importance especially in early stages280 Journal of Hepatology 201of tumor initiation and development, onewould expect respective
changes in gene expression signatures to be present in the early
stages of HCC investigated in the present study [8]. Nevertheless,
the authors were at least able to demonstrate the signiﬁcance of
these signatures in a subgroup analysis of patients with HCC clo-
ser to the scenarios where these signatures were originally iden-
tiﬁed. These included patients with more advanced stages of
HCC, larger tumors or vascular invasion.
Finally, the authors addressed the issue of sample variation
between repetitive biopsies taken from the same tumor nodule.
This issue is of signiﬁcant interest as sample variation in liver
ﬁbrosis is well established. In addition, Pawlik et al. have recently
reported the inaccuracy of needle core biopsies in predicting the
histologic grade of a tumor [9]. Villanueva et al. have, therefore,
investigated the reproducibility of the investigated signatures
on paired biopsies from 15 tumor specimens beyond 4 cm size.
In more than 80% of these paired biopsies the investigated signa-
tures were comparable between the biopsy obtained from the
tumor’s center and the periphery. Although this does not neces-
sarily hold true for smaller samples, which were the main focus
of the presented work, and the number of samples was rather
low, it provides at least some evidence for stability of genetic sig-
natures in paired biopsies and suggests a low inﬂuence of sam-
pling error.
Together, summarizing the results provided by Villaneuva et
al. these data provide a signiﬁcant step ahead not only in the
identiﬁcation of genetic signatures predicting HCC recurrence
but also in the evaluation of reported signatures in an indepen-
dent data set. Thus, this work is certainly a milestone in investi-
gating the genetics of HCC.
Furthermore, this work presents the direction of future
development of genetic biomarker identiﬁcation in HCC, as
one of the major challenges will be the integration of the avail-
able vast amount of data and the assembly of cumulative
hypotheses in translational science. Therefore, the development
of powerful bioinformatics resources able to cope with the mul-
tiple challenges of data integration (annotation, interaction,
technical platforms, etc.) will be essential. An integration of
transcriptomic genomic and epigenomic changes will be an
extremely complex challenge, even more considering the fact
that in normal liver tissue of model organisms approximately
25% of changes in gene expression are not accompanied by
simultaneous changes in protein abundance, particularly of
low expressed genes. However, unraveling the tight and com-
plex interactions between the diverse biological levels in HCC
development will certainly result in a much better understand-
ing of the underlying biology. Thus, the pursuit of biomarkers in
HCC will lead to a whole new perception of HCC development
and subsequently disclose novel strategies for the diagnosis
and treatment of HCC [10]. Therefore, tight integration of exper-
tise and knowledge from clinicians, biologists and bioinformati-
cians will be essential to achieve this ambitious goal. Thus, the
presented work by Villaneuva et al. is a valuable step ahead in
this direction.Conﬂict of interest
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